203 related articles for article (PubMed ID: 37020867)
1. Venetoclax resistance induced by activated T cells can be counteracted by sphingosine kinase inhibitors in chronic lymphocytic leukemia.
Sarapura Martinez VJ; Buonincontro B; Cassarino C; Bernatowiez J; Colado A; Cordini G; Custidiano MDR; Mahuad C; Pavlovsky MA; Bezares RF; Favale NO; Vermeulen M; Borge M; Giordano M; Gamberale R
Front Oncol; 2023; 13():1143881. PubMed ID: 37020867
[TBL] [Abstract][Full Text] [Related]
2. Venetoclax-resistant CLL cells show a highly activated and proliferative phenotype.
Elias EE; Sarapura Martinez VJ; Amondarain M; Colado A; Cordini G; Bezares RF; Fernandez Grecco H; Custidiano MDR; Sánchez Ávalos JC; Garate G; Pavlovsky MA; Borge M; Giordano M; Gamberale R
Cancer Immunol Immunother; 2022 Apr; 71(4):979-987. PubMed ID: 34467417
[TBL] [Abstract][Full Text] [Related]
3. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
[TBL] [Abstract][Full Text] [Related]
4. CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells.
Martens AWJ; Janssen SR; Derks IAM; Adams Iii HC; Izhak L; van Kampen R; Tonino SH; Eldering E; van der Windt GJW; Kater AP
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581054
[TBL] [Abstract][Full Text] [Related]
5. Mcl-1 and Bcl-xL levels predict responsiveness to dual MEK/Bcl-2 inhibition in B-cell malignancies.
Melvold K; Giliberto M; Karlsen L; Ayuda-Durán P; Hanes R; Holien T; Enserink J; Brown JR; Tjønnfjord GE; Taskén K; Skånland SS
Mol Oncol; 2022 Mar; 16(5):1153-1170. PubMed ID: 34861096
[TBL] [Abstract][Full Text] [Related]
6. High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells.
Oppermann S; Ylanko J; Shi Y; Hariharan S; Oakes CC; Brauer PM; Zúñiga-Pflücker JC; Leber B; Spaner DE; Andrews DW
Blood; 2016 Aug; 128(7):934-47. PubMed ID: 27297795
[TBL] [Abstract][Full Text] [Related]
7. Targeting Mcl-1 by AMG-176 During Ibrutinib and Venetoclax Therapy in Chronic Lymphocytic Leukemia.
Yi X; Jain N; Iles LR; Ayres ML; Wierda WG; Gandhi V
Front Oncol; 2022; 12():833714. PubMed ID: 35273915
[TBL] [Abstract][Full Text] [Related]
8. JAK-STAT signalling shapes the NF-κB response in CLL towards venetoclax sensitivity or resistance via Bcl-XL.
Haselager MV; Thijssen R; Bax D; Both D; De Boer F; Mackay S; Dubois J; Mellink C; Kater AP; Eldering E
Mol Oncol; 2023 Jun; 17(6):1112-1128. PubMed ID: 36550750
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of p38 MAPK or immunoproteasome overcomes resistance of chronic lymphocytic leukemia cells to Bcl-2 antagonist venetoclax.
Avsec D; Škrlj Miklavčič M; Burnik T; Kandušer M; Bizjak M; Podgornik H; Mlinarič-Raščan I
Cell Death Dis; 2022 Oct; 13(10):860. PubMed ID: 36209148
[TBL] [Abstract][Full Text] [Related]
10. Notch2 Increases the Resistance to Venetoclax-Induced Apoptosis in Chronic Lymphocytic Leukemia B Cells by Inducing Mcl-1.
Fiorcari S; Maffei R; Atene CG; Mesini N; Maccaferri M; Leonardi G; Martinelli S; Paolini A; Nasillo V; Debbia G; Potenza L; Luppi M; Marasca R
Front Oncol; 2021; 11():777587. PubMed ID: 35070982
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia.
Cervantes-Gomez F; Lamothe B; Woyach JA; Wierda WG; Keating MJ; Balakrishnan K; Gandhi V
Clin Cancer Res; 2015 Aug; 21(16):3705-15. PubMed ID: 25829398
[TBL] [Abstract][Full Text] [Related]
12. Microenvironmental agonists generate
Jayappa KD; Portell CA; Gordon VL; Capaldo BJ; Bekiranov S; Axelrod MJ; Brett LK; Wulfkuhle JD; Gallagher RI; Petricoin EF; Bender TP; Williams ME; Weber MJ
Blood Adv; 2017 Jun; 1(14):933-946. PubMed ID: 29034364
[No Abstract] [Full Text] [Related]
13. High expression level of ROR1 and ROR1-signaling associates with venetoclax resistance in chronic lymphocytic leukemia.
Ghia EM; Rassenti LZ; Choi MY; Quijada-Álamo M; Chu E; Widhopf GF; Kipps TJ
Leukemia; 2022 Jun; 36(6):1609-1618. PubMed ID: 35418613
[TBL] [Abstract][Full Text] [Related]
14. Aberrantly expressed Wnt5a in nurse-like cells drives resistance to Venetoclax in chronic lymphocytic leukemia.
Guo Y; Pei H; Lu B; Zhang D; Zhao Y; Wu F; Sun H; Huang J; Li P; Yi C; Zhu C; Pan Y; Wu S; Chen C; Xu X; Chen Y
Cell Death Discov; 2022 Feb; 8(1):82. PubMed ID: 35210425
[TBL] [Abstract][Full Text] [Related]
15. Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial.
Jain N; Keating M; Thompson P; Ferrajoli A; Burger JA; Borthakur G; Takahashi K; Estrov Z; Sasaki K; Fowler N; Kadia T; Konopleva M; Alvarado Y; Yilmaz M; DiNardo C; Bose P; Ohanian M; Pemmaraju N; Jabbour E; Kanagal-Shamanna R; Patel K; Wang W; Jorgensen J; Wang SA; Garg N; Wang X; Wei C; Cruz N; Ayala A; Plunkett W; Kantarjian H; Gandhi V; Wierda WG
JAMA Oncol; 2021 Aug; 7(8):1213-1219. PubMed ID: 34110383
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of casein kinase 2 sensitizes mantle cell lymphoma to venetoclax through MCL-1 downregulation.
Thus YJ; De Rooij MFM; Swier N; Beijersbergen RL; Guikema JEJ; Kersten MJ; Eldering E; Pals ST; Kater AP; Spaargaren M
Haematologica; 2023 Mar; 108(3):797-810. PubMed ID: 36226498
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis and Treatment of Chronic Lymphocytic Leukemia: A Review.
Shadman M
JAMA; 2023 Mar; 329(11):918-932. PubMed ID: 36943212
[TBL] [Abstract][Full Text] [Related]
18. Sphingosine kinase inhibitors decrease viability and induce cell death in natural killer-large granular lymphocyte leukemia.
LeBlanc FR; Liu X; Hengst J; Fox T; Calvert V; Petricoin EF; Yun J; Feith DJ; Loughran TP
Cancer Biol Ther; 2015; 16(12):1830-40. PubMed ID: 26252351
[TBL] [Abstract][Full Text] [Related]
19. Targeting Autophagy Triggers Apoptosis and Complements the Action of Venetoclax in Chronic Lymphocytic Leukemia Cells.
Avsec D; Jakoš Djordjevič AT; Kandušer M; Podgornik H; Škerget M; Mlinarič-Raščan I
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572784
[TBL] [Abstract][Full Text] [Related]
20. Potential of BCL2 as a target for chronic lymphocytic leukemia treatment.
Moia R; Diop F; Favini C; Kodipad AA; Gaidano G
Expert Rev Hematol; 2018 May; 11(5):391-402. PubMed ID: 29561706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
